Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
03 04 2023
03 04 2023
Historique:
received:
17
08
2022
revised:
09
12
2022
accepted:
23
01
2023
medline:
4
4
2023
pubmed:
25
1
2023
entrez:
24
1
2023
Statut:
ppublish
Résumé
Clinical genomic sequencing of pediatric tumors is increasingly uncovering pathogenic variants in adult-onset cancer predisposition genes (aoCPG). Nevertheless, it remains poorly understood how often aoCPG variants are of germline origin and whether they influence tumor molecular profiles and/or clinical care. In this study, we examined the prevalence, spectrum, and impacts of aoCPG variants on tumor genomic features and patient management at our institution. This is a retrospective study of 1,018 children with cancer who underwent clinical genomic sequencing of their tumors. Tumor genomic data were queried for pathogenic variants affecting 24 preselected aoCPGs. Available tumor whole-genome sequencing (WGS) data were evaluated for second hit mutations, loss of heterozygosity (LOH), DNA mutational signatures, and homologous recombination deficiency (HRD). Patients whose tumors harbored one or more pathogenic aoCPG variants underwent subsequent germline testing based on hereditary cancer evaluation and family or provider preference. Thirty-three patients (3%) had tumors harboring pathogenic variants affecting one or more aoCPGs. Among 21 tumors with sufficient WGS sequencing data, six (29%) harbored a second hit or LOH affecting the remaining aoCPG allele with four of these six tumors (67%) also exhibiting a DNA mutational signature consistent with the altered aoCPG. Two additional tumors demonstrated HRD, of uncertain relation to the identified aoCPG variant. Twenty-one of 26 patients (81%) completing germline testing were positive for the aoCPG variant in the germline. All germline-positive patients were counseled regarding future cancer risks, surveillance, and risk-reducing measures. No patients had immediate cancer therapy changed due to aoCPG data. AoCPG variants are rare in pediatric tumors; however, many originate in the germline. Almost one third of tumor aoCPG variants examined exhibited a second hit and/or conferred an abnormal DNA mutational profile suggesting a role in tumor formation. aoCPG information aids in cancer risk prediction but is not commonly used to alter the treatment of pediatric cancers.
Identifiants
pubmed: 36693186
pii: 716156
doi: 10.1158/1078-0432.CCR-22-2482
pmc: PMC10642481
mid: NIHMS1936807
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1243-1251Subventions
Organisme : NCI NIH HHS
ID : R01 CA241452
Pays : United States
Informations de copyright
©2023 American Association for Cancer Research.
Références
Clin Cancer Res. 2018 Apr 1;24(7):1594-1603
pubmed: 29351919
BMC Pediatr. 2020 May 15;20(1):222
pubmed: 32414353
J Natl Cancer Inst. 2021 Jul 1;113(7):875-883
pubmed: 33372952
J Law Med Ethics. 2015 Fall;43(3):552-8
pubmed: 26479565
Curr Hematol Malig Rep. 2022 Aug;17(4):94-104
pubmed: 35674998
Nat Cancer. 2021 Mar;2:357-365
pubmed: 34308366
J Clin Oncol. 2020 Aug 20;38(24):2728-2740
pubmed: 32496904
J Mol Diagn. 2016 Sep;18(5):605-619
pubmed: 27542512
Nat Med. 2017 Apr;23(4):517-525
pubmed: 28288110
Bioinformatics. 2012 Feb 1;28(3):311-7
pubmed: 22155872
Genet Med. 2016 Aug;18(8):763-4
pubmed: 26820067
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):219-227
pubmed: 33275754
Ann Oncol. 2015 Jan;26(1):64-70
pubmed: 25319062
J Natl Cancer Inst. 2015 Nov 20;108(4):
pubmed: 26590952
JAMA. 2015 Sep 1;314(9):913-25
pubmed: 26325560
Genet Med. 2020 Jul;22(7):1142-1148
pubmed: 32321997
NPJ Breast Cancer. 2018 Jul 2;4:16
pubmed: 29978035
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Bioinformatics. 2018 Jan 15;34(2):330-337
pubmed: 29028923
Nat Commun. 2015 Dec 03;6:8940
pubmed: 26632267
Clin Cancer Res. 2016 Aug 1;22(15):3764-73
pubmed: 26957554
Cancer Discov. 2021 Dec 1;11(12):3008-3027
pubmed: 34301788
Nat Cancer. 2020 Feb;1(2):249-263
pubmed: 32118208
N Engl J Med. 2015 Dec 10;373(24):2336-2346
pubmed: 26580448
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
J Natl Cancer Inst. 2004 Feb 18;96(4):261-8
pubmed: 14970275
J Oncol Pract. 2019 Sep;15(9):465-473
pubmed: 31509718
Genome Biol. 2016 Aug 24;17(1):178
pubmed: 27557938
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
JAMA Netw Open. 2020 Oct 1;3(10):e2019452
pubmed: 33026450
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Cold Spring Harb Perspect Med. 2020 Aug 3;10(8):
pubmed: 31570381
Genet Med. 2016 Aug;18(8):755-62
pubmed: 26741411
N Engl J Med. 2021 Feb 4;384(5):440-451
pubmed: 33471974
Sci Rep. 2021 Mar 5;11(1):5307
pubmed: 33674644
Cell Genom. 2022 Nov 09;2(11):None
pubmed: 36388765
Eur J Hum Genet. 2021 Aug;29(8):1301-1311
pubmed: 33840814
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
JAMA Oncol. 2016 May 01;2(5):608-615
pubmed: 26822149
JAMA Oncol. 2020 May 1;6(5):724-734
pubmed: 32191290
J Natl Compr Canc Netw. 2021 Jan 06;19(1):77-102
pubmed: 33406487
J Clin Oncol. 2018 Jul 10;36(20):2078-2087
pubmed: 29847298
Nat Med. 2020 Nov;26(11):1742-1753
pubmed: 33020650
Cancer Discov. 2021 Nov;11(11):2846-2867
pubmed: 34103329
Nature. 2018 Mar 15;555(7696):321-327
pubmed: 29489754
Cancer Prev Res (Phila). 2021 Apr;14(4):433-440
pubmed: 33509806
JAMA Oncol. 2019 Sep 1;5(9):1362-1364
pubmed: 31343663
JAMA Oncol. 2016 May 01;2(5):616-624
pubmed: 26822237
PLoS Genet. 2020 Dec 17;16(12):e1009231
pubmed: 33332384
Nat Methods. 2018 Aug;15(8):591-594
pubmed: 30013048
Ann Oncol. 2016 May;27(5):795-800
pubmed: 26787237
Lancet Oncol. 2018 Jun;19(6):785-798
pubmed: 29753700
JCO Precis Oncol. 2019;3:
pubmed: 32783018
Nat Genet. 2017 Oct;49(10):1476-1486
pubmed: 28825726
J Natl Cancer Inst. 2018 Sep 1;110(9):1030-1034
pubmed: 29506079
Gastroenterology. 1999 Jun;116(6):1453-6
pubmed: 10348829
Front Pediatr. 2017 Dec 12;5:265
pubmed: 29312904
Clin Cancer Res. 2016 Aug 1;22(15):3810-20
pubmed: 26994145
Genome Med. 2016 Dec 23;8(1):133
pubmed: 28007021
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
J Pathol. 2018 Apr;244(5):610-615
pubmed: 29293272
Nat Commun. 2020 May 5;11(1):2206
pubmed: 32371905